Clinical trials: PD-L1
Lung Neoplasms
Envafolimab Combined With Endostar in the First-line Treatment of Advanced NSCLC
To evaluate the efficacy and safety of envafolimab combined with endostar in the first-line treatment of advanced Non-small Cell Lung Cancer With PD-L1 positive expression
- Trial name
- NCT05203276
- Testing
- Envafolimab, Endostar
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- The First People's Hospital of Lianyungang
Sepsis
PD-1/PD-L1 Pathway Study on Septic Patients
The investigators want to identify that whether PD-1/PD-L1 pathway will change in human sepsis, and whether PD-1/PD-L1 pathway play an important role in sepsis induced immunosuppression.
- Trial name
- NCT01161745
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Changhai Hospital
Diffuse Large B-cell Lymphoma, Hodgkin Lymphoma
BMS_PD-L1_onco : Assessment of the PD-L1 Protein as a Biomarker in Oncology and Hematology
Diffuse large B-cell lymphomas (DLBCLs) represent 25 to 30% of adult non-Hodgkin lymphomas in western countries. DLBCLs are aggressive cancer but potentially curable with multi-agent chemotherapy.
- Conditions
- Diffuse Large B-cell Lymphoma, Hodgkin Lymphoma, Metastatic Breastcancer, Non-small Cell Lung Cancer
- Trial name
- BMS_PD-L1 (NCT01660776)
- Where
- 4 sites in France
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- Rennes University Hospital
Conjunctivitis, Allergic
Treg Effector Function and Th2/Treg Ratio in Allergic Conjunctivitis: Effect of Desensitization Therapy
This study aims to evaluate the effector function and expression of TIGIT and PD-1 on Tregs, as well as the Th2/Treg ratio, in patients with allergic conjunctivitis with and without desensitization therapy, compared to healthy…
- Trial name
- INMUNOREG (NCT07171307)
- Where
- Mexico
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Instituto de Oftalmología Fundación Conde de Valenciana
Tumor, PD-L1
68Ga-NK224 PET Imaging of PD-L1 Expression in Cancers
To evaluate the potential usefulness of 68Ga-NK224 positron emission tomography/computed tomography (PET/CT) for the evaluation of PD-L1 expression in primary and/or metastatic tumors, compared with histopathological results.
- Trial name
- NCT06754345
- Where
- China
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- The First Affiliated Hospital of Xiamen University
Circulating Tumor Cells (CTCs), Immunotherapy
Predicting Clinical Efficacy of Immunotherapy Using Pre-treatment andContinuousMonitoring of PD-L1 TPS/CPS on CTCs, and Immunity Exhaustion Scores
Head and neck cancer is ranked among the fifth to eighth most prevalent cancers worldwide and is associated with a high mortality rate.
- Conditions
- Circulating Tumor Cells (CTCs), Immunotherapy, PD-L1 Expression, Liquidbiopsies
- Trial name
- NCT07396259
- Where
- Taiwan
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Chang Gung Memorial Hospital
Other Skin Changes Due to Chronic Exposure to Nonionizing Radiation
SUV PDL1/PD1 in Sun Damaged & Sun Protected Human Skin of Participants
The purpose of this research study is to look at how the proteins and genes in people's skin change when they're exposed to simulated sunlight.
- Trial name
- NCT06177106
- Testing
- Solar Simulated Light
- Where
- United States
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- University of Arizona
Non Small Cell Lung Cancer, Influenza Vaccine
Impact of Inactivated Trivalent Influenza Vaccine on NSCLC Patients Receiving PD-1 / PD-L1 Inhibitors
This project is to assess the immunogenicity, safety and overall survival impact of intramuscular injection of trivalent influenza vaccine in non-small cell lung cancer (NSCLC) patients with PD-1/PD-L1 inhibitor treatment.
- Trial name
- NCT04355806
- Testing
- PD-1/PD-L1 inhibitors, Inactivated trivalent influenza vaccine
- Where
- 2 sites in China
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China